125 related articles for article (PubMed ID: 10856431)
1. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone.
Nielsen D; Eriksen J; Maare C; Litman T; Kjaersgaard E; Plesner T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):363-70. PubMed ID: 10856431
[TBL] [Abstract][Full Text] [Related]
2. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
4. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Friche E; Danks MK; Beck WT
Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
[TBL] [Abstract][Full Text] [Related]
5. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N
Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202
[TBL] [Abstract][Full Text] [Related]
6. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
[TBL] [Abstract][Full Text] [Related]
7. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
8. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Lee JS; Scala S; Matsumoto Y; Dickstein B; Robey R; Zhan Z; Altenberg G; Bates SE
J Cell Biochem; 1997 Jun; 65(4):513-26. PubMed ID: 9178101
[TBL] [Abstract][Full Text] [Related]
9. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
[TBL] [Abstract][Full Text] [Related]
10. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line.
Taylor CW; Dalton WS; Parrish PR; Gleason MC; Bellamy WT; Thompson FH; Roe DJ; Trent JM
Br J Cancer; 1991 Jun; 63(6):923-9. PubMed ID: 1676902
[TBL] [Abstract][Full Text] [Related]
11. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
12. pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells.
Litman T; Pedersen SF; Kramhøft B; Skovsgaard T; Hoffmann EK
Cell Physiol Biochem; 1998; 8(3):138-50. PubMed ID: 9617476
[TBL] [Abstract][Full Text] [Related]
13. Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines.
Modrak DE; Draper MP; Levy SB
Biochem Pharmacol; 1997 Dec; 54(12):1297-306. PubMed ID: 9393672
[TBL] [Abstract][Full Text] [Related]
14. ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines.
Litman T; Nielsen D; Skovsgaard T; Zeuthen T; Stein WD
Biochim Biophys Acta; 1997 Aug; 1361(2):147-58. PubMed ID: 9300796
[TBL] [Abstract][Full Text] [Related]
15. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
[TBL] [Abstract][Full Text] [Related]
16. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
17. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
18. Relationship of VP-16 to the classical multidrug resistance phenotype.
Sehested M; Friche E; Jensen PB; Demant EJ
Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
[TBL] [Abstract][Full Text] [Related]
20. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):778-84. PubMed ID: 11473729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
